vs
ANI PHARMACEUTICALS INC（ANIP）与WORTHINGTON ENTERPRISES, INC.（WOR）财务数据对比。点击上方公司名可切换其他公司
WORTHINGTON ENTERPRISES, INC.的季度营收约是ANI PHARMACEUTICALS INC的1.3倍（$327.5M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 8.3%，领先2.8%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 19.5%），WORTHINGTON ENTERPRISES, INC.自由现金流更多（$39.1M vs $29.1M）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
沃辛顿实业是一家总部位于美国俄亥俄州哥伦布市的工业制造企业，下设消费品和建筑产品两大业务板块，设计生产丙烷、氧气、氦气压力容器，制冷及工业气瓶，露营与家用气瓶，以及用于存储、处理、加热、扩容和流量控制的供水系统罐体等多元化产品。
ANIP vs WOR — 直观对比
营收规模更大
WOR
是对方的1.3倍
$247.1M
营收增速更快
ANIP
高出10.2%
19.5%
净利率更高
ANIP
高出2.8%
8.3%
自由现金流更多
WOR
多$10.0M
$29.1M
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $327.5M |
| 净利润 | $27.5M | $27.3M |
| 毛利率 | — | 25.8% |
| 营业利润率 | 14.1% | 3.7% |
| 净利率 | 11.1% | 8.3% |
| 营收同比 | 29.6% | 19.5% |
| 净利润同比 | 367.5% | -3.3% |
| 每股收益（稀释后） | $1.14 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPWOR
| Q4 25 | $247.1M | $327.5M | ||
| Q3 25 | $227.8M | $303.7M | ||
| Q2 25 | $211.4M | — | ||
| Q1 25 | $197.1M | — | ||
| Q4 24 | $190.6M | — | ||
| Q3 24 | $148.3M | — | ||
| Q2 24 | $138.0M | — | ||
| Q1 24 | $137.4M | — |
净利润ANIPWOR
| Q4 25 | $27.5M | $27.3M | ||
| Q3 25 | $26.6M | $35.1M | ||
| Q2 25 | $8.5M | — | ||
| Q1 25 | $15.7M | — | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | — | ||
| Q2 24 | $-2.3M | — | ||
| Q1 24 | $18.2M | — |
毛利率ANIPWOR
| Q4 25 | — | 25.8% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ANIPWOR
| Q4 25 | 14.1% | 3.7% | ||
| Q3 25 | 15.9% | 3.0% | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 14.8% | — |
净利率ANIPWOR
| Q4 25 | 11.1% | 8.3% | ||
| Q3 25 | 11.7% | 11.6% | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 8.0% | — | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | -1.7% | — | ||
| Q1 24 | 13.2% | — |
每股收益（稀释后）ANIPWOR
| Q4 25 | $1.14 | $0.55 | ||
| Q3 25 | $1.13 | $0.70 | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $180.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $962.6M |
| 总资产 | $1.4B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPWOR
| Q4 25 | $285.6M | $180.3M | ||
| Q3 25 | $262.6M | $167.1M | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
股东权益ANIPWOR
| Q4 25 | $540.7M | $962.6M | ||
| Q3 25 | $505.8M | $959.1M | ||
| Q2 25 | $436.8M | — | ||
| Q1 25 | $418.6M | — | ||
| Q4 24 | $403.7M | — | ||
| Q3 24 | $405.9M | — | ||
| Q2 24 | $455.8M | — | ||
| Q1 24 | $452.0M | — |
总资产ANIPWOR
| Q4 25 | $1.4B | $1.8B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $920.8M | — | ||
| Q1 24 | $914.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $51.5M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $39.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 11.9% |
| 资本支出强度资本支出/营收 | 0.5% | 3.8% |
| 现金转化率经营现金流/净利润 | 1.10× | 1.89× |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPWOR
| Q4 25 | $30.4M | $51.5M | ||
| Q3 25 | $44.1M | $41.1M | ||
| Q2 25 | $75.8M | — | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $17.4M | — | ||
| Q1 24 | $18.3M | — |
自由现金流ANIPWOR
| Q4 25 | $29.1M | $39.1M | ||
| Q3 25 | $38.0M | $27.9M | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPWOR
| Q4 25 | 11.8% | 11.9% | ||
| Q3 25 | 16.7% | 9.2% | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPWOR
| Q4 25 | 0.5% | 3.8% | ||
| Q3 25 | 2.7% | 4.3% | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
现金转化率ANIPWOR
| Q4 25 | 1.10× | 1.89× | ||
| Q3 25 | 1.66× | 1.17× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
WOR
| Building Products | $207.5M | 63% |
| Equity Method Investment Nonconsolidated Investee Other | $120.7M | 37% |
